News Releases

Leading New Gene-based Therapies

Enochian BioSciences Announces the Successful Completion of an FDA Pre-IND for a Potential Cure for HIV: The Second Pre-IND in 1 month


Company encouraged by clear path to IND in near-term following its review of the FDA’s Center for Biologics Evaluation and Research written comments   LOS ANGELES, October 18, 2021 (NASDAQ: ENOB) − Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced the completion of an

Read more

Enochian BioSciences Announces the Successful Completion of an FDA Pre-IND for a Potential Cure for HIV: The Second Pre-IND in 1 month

October 18, 2021


Scientific Advisory Board Member Resigns Due to Conflict with Responsibilities with Important Public Sector Entity

October 15, 2021


Fireside Chat with Enochian BioSciences’ CEO, Dr. Mark Dybul at H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference

October 12, 2021


Enochian BioSciences Announces Its Successful Completion of FDA Pre-IND for a Potential Cure for Hepatitis B Virus Infection

September 27, 2021


Enochian BioSciences to Present to Investors at the H.C. Wainwright 23rd Annual Investment Conference

September 13, 2021


Distinguished Scientific and Public Health Leaders to Join Enochian BioSciences’ Scientific Advisory Board for Potential Inhaled Treatment and Prevention of All COVID-19 and Influenza Variants

August 30, 2021


Distinguished Scientific and Clinical Leader to Join Enochian BioSciences’ Hepatitis B Cure Scientific Advisory Board

August 23, 2021


Enochian BioSciences Names The Hon. Dr. Mark Dybul as Chief Executive Officer

July 20, 2021


Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection

July 12, 2021


Enochian BioSciences Announces Scientific Presentation of Elimination of HBV in Mice with No Evident Toxicity

June 30, 2021


Enochian BioSciences Announces Acquisition of Exclusive License for Potential Pan-Coronavirus and Pan-Influenza Inhaled Treatment and Prevention Technology

June 21, 2021


Enochian BioSciences Announces $29 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

June 14, 2021